Armata Pharmaceuticals Adds Pfizer Executive to Board of Directors

The latest update is out from Armata Pharmaceuticals ( (ARMP) ).

On April 27, 2026, Armata Pharmaceuticals announced that Daniel B. Gilmer, Ph.D., a senior commercial executive at Pfizer, has joined its Board of Directors effective April 24, 2026. His appointment brings extensive experience in scientific discovery, commercial strategy, and patient access, including leadership roles in launching first-in-class anti-infective therapies and diagnostics.

Gilmer currently leads Pfizer’s U.S. Commercial Quality team overseeing more than 50 brands and previously spearheaded the U.S. launch of antiviral PAXLOVID after FDA approval. As a co-inventor of the first-in-class Streptococcus bacteriophage lysin Exebacase and a recognized expert in antimicrobial resistance, his addition is expected to strengthen Armata’s push to commercialize its phage-based pipeline and sharpen its competitive position in the fight against antibiotic-resistant infections.

The most recent analyst rating on (ARMP) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Armata Pharmaceuticals stock, see the ARMP Stock Forecast page.

Spark’s Take on ARMP Stock

According to Spark, TipRanks’ AI Analyst, ARMP is a Neutral.

The score is held down primarily by very weak financial performance (persistent losses, ongoing cash burn, and negative equity), partially offset by strong bullish technical momentum and favorable clinical/regulatory milestones (FDA Phase 3 support and QIDP designation). Valuation remains unattractive/unclear due to negative earnings and no dividend yield.

To see Spark’s full report on ARMP stock, click here.

More about Armata Pharmaceuticals

Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company focused on developing high-purity, pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. The company is advancing a pipeline of natural and synthetic phage candidates targeting pathogens such as Pseudomonas aeruginosa and S. aureus, supported by in-house phage-specific cGMP manufacturing aimed at eventual full commercialization.

Armata’s strategy positions it within the emerging phage therapy segment of the anti-infectives market, where rising antimicrobial resistance is driving demand for novel targeted approaches. By controlling both R&D and manufacturing, the company seeks to differentiate itself as a fully integrated player capable of moving candidates efficiently from bench to clinic and ultimately to market.

Average Trading Volume: 47,236

Technical Sentiment Signal: Buy

Current Market Cap: $473.3M

For detailed information about ARMP stock, go to TipRanks’ Stock Analysis page.